CH678492A5 - - Google Patents

Download PDF

Info

Publication number
CH678492A5
CH678492A5 CH3632/88A CH363288A CH678492A5 CH 678492 A5 CH678492 A5 CH 678492A5 CH 3632/88 A CH3632/88 A CH 3632/88A CH 363288 A CH363288 A CH 363288A CH 678492 A5 CH678492 A5 CH 678492A5
Authority
CH
Switzerland
Prior art keywords
tumor
pyridine
mpl
microorganism
cell wall
Prior art date
Application number
CH3632/88A
Other languages
German (de)
English (en)
Inventor
John Leonard Cantrell
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of CH678492A5 publication Critical patent/CH678492A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CH3632/88A 1987-09-30 1988-09-30 CH678492A5 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/102,909 US4877611A (en) 1986-04-15 1987-09-30 Vaccine containing tumor antigens and adjuvants

Publications (1)

Publication Number Publication Date
CH678492A5 true CH678492A5 (enExample) 1991-09-30

Family

ID=22292343

Family Applications (1)

Application Number Title Priority Date Filing Date
CH3632/88A CH678492A5 (enExample) 1987-09-30 1988-09-30

Country Status (10)

Country Link
US (1) US4877611A (enExample)
JP (1) JPH01163130A (enExample)
BE (1) BE1001634A4 (enExample)
CA (1) CA1333152C (enExample)
CH (1) CH678492A5 (enExample)
DE (1) DE3833319A1 (enExample)
FR (1) FR2620941B1 (enExample)
GB (1) GB2210557B (enExample)
IT (1) IT1226861B (enExample)
NL (1) NL8802393A (enExample)

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212085A (en) * 1987-12-09 1993-05-18 The General Hospital Corporation Sf-25 colon adenocarcinoma antigen, and antibodies with recognize this antigen
EP0420848B1 (en) * 1987-12-09 1996-02-07 The General Hospital Corporation Carcinoma-associated antigens, and antibodies which recognize these antigens
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
US6093406A (en) * 1988-06-02 2000-07-25 The United States Of America As Represented By The Secretary Of The Army Vaccine for induction of immunity to malaria
AU4338189A (en) * 1988-09-23 1990-04-18 University Of Southern California Immunotherapy vaccine for melanoma tumors
US4963364A (en) * 1989-04-10 1990-10-16 Fox Sidney W Microencapsulated antitumor agent
ES2106033T3 (es) * 1989-05-19 1997-11-01 Genentech Inc Dominio extracelular de her2.
US6177083B1 (en) * 1990-07-26 2001-01-23 Evax Technologies Gmbh Process for the production of vaccines and their use
CA2049548C (en) * 1990-08-20 2002-07-02 Kiyoshi Yoshimura Lps-producing bacteria, lpss, and lps-containing medicines and veterinary medicines
US5413993A (en) * 1991-08-20 1995-05-09 Gen-Ichiro Soma Method for the treatment of narcotic withdrawal symptoms in animals using lipopolysaccharides
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
ATE156710T1 (de) * 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
WO1994021297A1 (en) * 1993-03-16 1994-09-29 Samuel Bogoch Recognin vaccines
NZ263538A (en) * 1993-03-23 1996-10-28 Smithkline Beecham Biolog Vaccine compositions of 3-o-deacylated monophosphoryl lipid a
AU686660B2 (en) * 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
USD365131S (en) 1994-05-25 1995-12-12 Royal Grip, Inc. Golf club grip
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
FR2733151B1 (fr) * 1995-04-20 1997-05-23 Seppic Sa Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines
US6117432A (en) * 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US6689370B1 (en) 1995-04-20 2004-02-10 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US6303584B1 (en) 1996-11-20 2001-10-16 The University Of Montana Water soluble lipidated arabinogalactan
DK1003525T3 (da) 1997-08-05 2003-03-24 Bioniche Life Sciences Inc Præparat og fremgangsmåde til regulering af celleproliferation og celledød
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
US7534443B1 (en) * 1998-07-16 2009-05-19 Ichiro Azuma Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
DK2272859T3 (en) 1998-08-07 2015-01-19 Univ Washington Immunological herpes simplex virus antigens and methods for their use
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
EP1144642B1 (en) 1998-12-08 2010-05-26 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
CN1370182A (zh) 1999-04-02 2002-09-18 科里克萨有限公司 用于治疗和诊断肺癌的化合物和方法
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
RU2152800C1 (ru) * 1999-12-08 2000-07-20 Зыбин Дмитрий Владимирович Способ культивирования и модификации гетерогенных клеток млекопитающих
CN100445380C (zh) * 1999-12-13 2008-12-24 拜昂尼科生命科学有限公司 治疗用合成寡核苷酸
EP1250152B1 (en) * 1999-12-28 2013-05-15 Bioniche Urology IP Inc. Synergistic composition containing hyaluronic acid in the treatment of cancer
ATE487733T1 (de) 2000-02-23 2010-11-15 Glaxosmithkline Biolog Sa Neue verbindungen
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
AU2001269695B2 (en) 2000-05-19 2007-02-15 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds
WO2001098460A2 (en) * 2000-06-20 2001-12-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
ATE396265T1 (de) 2000-06-28 2008-06-15 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
DE10132502A1 (de) * 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
EP2241309A3 (en) 2001-07-10 2012-12-26 Corixa Corporation Methods for encapsulation of proteins and adjuants in microspheres
US20060068405A1 (en) * 2004-01-27 2006-03-30 Alex Diber Methods and systems for annotating biomolecular sequences
AU2002362368B2 (en) 2001-09-20 2006-09-21 Glaxo Group Limited HIV-gag codon-optimised DNA vaccines
WO2003028758A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
WO2003053220A2 (en) 2001-12-17 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2003213640A1 (en) * 2002-02-28 2003-09-16 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
ATE414176T1 (de) 2002-07-18 2008-11-15 Univ Washington Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
AU2003254792A1 (en) * 2002-08-02 2004-02-23 Sumitomo Pharmaceuticals Company, Limited Bacterial cell wall skeleton component preparaion
NZ541504A (en) * 2002-11-13 2009-04-30 Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein E and methods of use
WO2004062599A2 (en) 2003-01-06 2004-07-29 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
US20080199493A1 (en) 2004-05-25 2008-08-21 Picker Louis J Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
CA2565500A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
WO2006042156A2 (en) 2004-10-08 2006-04-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS represneted by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Modulation of replicative fitness by using less frequently used synonymous codons
WO2006065549A2 (en) 2004-12-03 2006-06-22 Medical University Of Ohio Attenuated vaccine useful for immunizations against coccidioides spp. infections
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
MX2007012108A (es) 2005-03-31 2007-12-05 Glaxosmithkline Biolog Sa Vacunas contra infeccion por chlamydia.
WO2006117240A2 (en) 2005-04-29 2006-11-09 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating m tuberculosis infection
CA2616026A1 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
JP5714799B2 (ja) 2005-10-18 2015-05-07 ノババックス インコーポレイテッド 機能的インフルエンザウイルス様粒子（ｖｌｐ）
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
LT2486938T (lt) 2006-09-26 2018-06-25 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
JP5578390B2 (ja) * 2007-03-05 2014-08-27 株式会社 Ｍｂｒ 細菌細胞壁骨格成分の製造方法
MX351247B (es) 2007-04-04 2017-10-05 Infectious Disease Res Institute Star Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
AR066405A1 (es) * 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
JP2010533737A (ja) 2007-07-19 2010-10-28 ノババックス，インコーポレイテッド キメラ水痘帯状疱疹ウイルス−ウイルス様粒子
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
EA201692127A1 (ru) 2007-11-07 2017-08-31 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческим dec-205
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
AU2009208607B2 (en) * 2008-01-31 2013-08-01 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP3062106B1 (en) 2008-04-16 2020-11-11 The Johns Hopkins University Method for determining androgen receptor variants in prostate cancer
CN102131830A (zh) * 2008-07-18 2011-07-20 魁北克益得生物医学公司 嵌合呼吸道合胞病毒多肽抗原
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
CN102317308A (zh) 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
PT3067064T (pt) 2008-12-09 2020-06-16 Novavax Inc Proteínas f vsr modificadas e processos para a sua utilização
JP6058266B2 (ja) 2009-02-17 2017-01-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アルミニウム不含アジュバントを添加した不活化デング熱ウイルスワクチン
JP5830015B2 (ja) 2009-06-05 2015-12-09 インフェクシャス ディズィーズ リサーチ インスティチュート 合成グルコピラノシル脂質アジュバント
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
EA023054B1 (ru) 2009-06-24 2016-04-29 Глэксосмитклайн Байолоджикалз С.А. Рекомбинантные антигены pcb
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
EP2451950B9 (en) 2009-07-06 2016-11-23 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
KR101125764B1 (ko) 2010-01-27 2012-03-27 백태현 항산균 세포벽골격을 이용한 백신매개체 및 그에 의한 백신의 제조 방법
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
RU2603274C2 (ru) * 2010-07-02 2016-11-27 Интервет Интернэшнл Б.В. Вакцина против ehrlichia canis
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
WO2012049317A2 (en) 2010-10-15 2012-04-19 Glaxosmithkline Biologicals S.A. Novel antigen
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
HUE034247T2 (en) 2010-11-05 2018-02-28 Novavax Inc RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
EP2637687B1 (en) 2010-11-08 2021-01-06 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
EP3593813A1 (en) 2010-12-14 2020-01-15 GlaxoSmithKline Biologicals S.A. Mycobacterium antigenic composition
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
WO2012106356A2 (en) 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
CN103596586A (zh) 2011-04-08 2014-02-19 免疫设计公司 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
PL3275892T3 (pl) 2011-05-13 2020-09-07 Glaxosmithkline Biologicals S.A. Przedfuzyjne antygeny RSV F
EP2723365A1 (en) 2011-06-21 2014-04-30 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
CA2866582A1 (en) 2012-03-18 2013-09-26 Brigitte Desiree Alberte Colau Method of vaccination against human papillomavirus
HUE039215T2 (hu) 2012-05-16 2018-12-28 Immune Design Corp Vakcinák HSV-2-höz
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
US20150182612A1 (en) 2012-08-03 2015-07-02 Infectious Disease Research Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
EP2928489B1 (en) 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition
PL2970398T3 (pl) 2013-03-13 2024-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Białka f rsv przed fuzją i ich zastosowanie
CN105682662A (zh) 2013-03-14 2016-06-15 马里兰大学巴尔的摩校区 雄激素受体减量调节剂及其用途
EP3608332B1 (en) 2013-03-15 2022-06-01 GlaxoSmithKline Biologicals SA Vaccine against human rhinovirus
EP2978447B1 (en) 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3632458B1 (en) 2013-07-26 2025-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
MX386142B (es) 2013-09-19 2025-03-18 Novavax Inc COMPOSICIONES INMUNOGÉNICAS PARA EL CORONAVIRUS DEL SÍNDROME RESPIRATORIO DE ORIENTE MEDIO (MERS-CoV) Y SUS USOS.
WO2015179404A1 (en) 2014-05-19 2015-11-26 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
EP3888676A1 (en) 2014-06-13 2021-10-06 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
CA2952118A1 (en) 2014-06-25 2015-12-30 Glaxosmithkline Biologicals S.A. Clostridium difficile immunogenic composition
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
JP6860476B2 (ja) 2014-08-25 2021-04-14 ザ ジョンズ ホプキンズ ユニヴァーシティー 前立腺がん治療に関する方法及び組成物
CN107278206B (zh) 2014-12-19 2021-04-02 雷根尼桑斯公司 结合人c6的抗体及其用途
JP6647315B2 (ja) 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
EP3302544A4 (en) 2015-05-26 2019-01-09 Ohio State Innovation Foundation NANOPARTICLE-BASED VACCINE STRATEGY AGAINST SWINE INFLUENZA VIRUS
US20170226171A1 (en) * 2016-02-09 2017-08-10 Vaccinogen, Inc. Adenocarcinoma antigenic determinants and methods
AU2017225769B2 (en) 2016-03-02 2023-01-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
KR20190009308A (ko) 2016-05-21 2019-01-28 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 2차 결핵 및 비결핵성 마이코박테리아 감염을 치료하기 위한 조성물 및 방법
KR20200138418A (ko) 2016-05-27 2020-12-09 이투빅스 코포레이션 네오에피토프 백신 조성물 및 이의 사용 방법
MX2019003035A (es) 2016-09-16 2019-09-13 Infectious Disease Res Inst Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
BR112019011286A2 (pt) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals Sa métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
UA129243C2 (uk) 2017-04-19 2025-02-26 Інстітьют Фо Рісьорч Ін Біомедцін Антитіло, що зв'язується зі спорозоїтами p. falciparum
US20210187098A1 (en) 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
JP7291633B2 (ja) 2017-05-30 2023-06-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アジュバントを製造する方法
IL271384B2 (en) 2017-06-15 2025-02-01 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and their uses
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
WO2019035963A1 (en) 2017-08-16 2019-02-21 Ohio State Innovation Foundation NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
US20210046177A1 (en) 2018-01-26 2021-02-18 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
MX2020010913A (es) 2018-04-17 2021-01-08 Celldex Therapeutics Inc Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
ES3038006T3 (en) 2018-07-31 2025-10-08 Glaxosmithkline Biologicals Sa Antigen purification method
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US20220133872A1 (en) * 2019-02-08 2022-05-05 University Of Florida Research Foundation, Inc. A monophosphoryl lipid-a liposome based cancer vaccine
CA3142300C (en) 2019-06-05 2025-02-04 Glaxosmithkline Biologicals Sa SAPONIN PURIFICATION
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4028051A1 (en) 2019-09-09 2022-07-20 GlaxoSmithKline Biologicals S.A. Immunotherapeutic compositions
IL291821A (en) 2019-10-02 2022-06-01 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use
EP4077356A1 (en) 2019-12-19 2022-10-26 GlaxoSmithKline Biologicals SA S. aureus antigens and compositions thereof
BR112022013720A2 (pt) 2020-01-16 2022-10-11 Janssen Pharmaceuticals Inc Mutante fimh, composições com o mesmo e seu uso
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021178637A1 (en) 2020-03-05 2021-09-10 Iowa State University Research Foundation, Inc. IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
WO2021214766A1 (en) 2020-04-21 2021-10-28 Yeda Research And Development Co. Ltd. Methods of diagnosing viral infections and vaccines thereto
CA3181627A1 (en) 2020-05-05 2021-11-11 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
EP4158352A1 (en) 2020-06-01 2023-04-05 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
EP4188427A1 (en) 2020-08-03 2023-06-07 GlaxoSmithKline Biologicals S.A. Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
JP2023553854A (ja) 2020-12-02 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ドナー鎖補完性ｆｉｍｈ
MX2023006769A (es) 2020-12-09 2023-08-18 Glaxosmithkline Biologicals Sa Modificacion de saponinas.
CA3202311A1 (en) 2020-12-24 2022-06-30 Anne Osbourn Methods and enzymes for producing quillaic acid derivatives
AU2022207740B2 (en) 2021-01-12 2024-06-06 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
MX2023009456A (es) 2021-02-11 2023-08-28 Glaxosmithkline Biologicals Sa Preparacion de la vacuna contra el vph.
TW202304504A (zh) 2021-04-01 2023-02-01 美商詹森藥物公司 大腸桿菌ｏ１８生物軛合物之生產
US20240417459A1 (en) 2021-04-09 2024-12-19 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US20250207166A1 (en) 2022-03-25 2025-06-26 Plant Bioscience Limited Biosynthesis
CA3253348A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa ENZYMATIC MODIFICATION OF SAPONINS
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
IL319329A (en) 2022-09-09 2025-05-01 Access To Advanced Health Inst Immunogenic vaccine composition incorporating saponin
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
AU2024233763A1 (en) 2023-03-03 2025-10-16 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (enExample) * 1971-11-19 1975-02-07 Anvar
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505903A (en) * 1982-06-30 1985-03-19 Ribi Immunochem Research, Inc. Pyridine soluble extract of a microorganism
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use

Also Published As

Publication number Publication date
CA1333152C (en) 1994-11-22
IT1226861B (it) 1991-02-19
JPH01163130A (ja) 1989-06-27
DE3833319A1 (de) 1989-04-13
BE1001634A4 (fr) 1990-01-02
IT8822145A0 (it) 1988-09-30
FR2620941A1 (fr) 1989-03-31
US4877611A (en) 1989-10-31
GB2210557B (en) 1991-11-13
GB2210557A (en) 1989-06-14
NL8802393A (nl) 1989-04-17
GB8822749D0 (en) 1988-11-02
JPH0575731B2 (enExample) 1993-10-21
DE3833319C2 (enExample) 1992-06-11
FR2620941B1 (fr) 1990-08-10

Similar Documents

Publication Publication Date Title
DE3833319C2 (enExample)
DE3318567C2 (de) Therapeutisches Mittel, enthaltend gereinigtes, entgiftetes Endotoxin, Zellwandgerüst und Trehalosedimycolat
DE69116377T2 (de) Mycobacterium vaccae in der behandlung von uveitis
DE3318569A1 (de) Verfahren zur herstellung von gereinigtem, entgiftetem endotoxin
DE3434766C2 (de) Pharmazeutisches Präparat
US4520019A (en) Stable composition and preparation thereof
DE69418183T2 (de) Immunotherapeutische zubereitung
DE2908241A1 (de) Bakterienzellenextrakt, verfahren zu seiner herstellung, diesen bakterienzellenextrakt enthaltende antitumoraktive zubereitung und adjuvanspraeparat
DE69526935T2 (de) Verwendung von mycobacterium zur tumorbehandlung
DE3318568A1 (de) Therapeutische zusammensetzung enthaltend gereinigtes, entgiftetes endotoxin, trehalosedimycolat und ein mit azeton ausgefaelltes nebenprodukt von mit chloroform-methanol extrahierten endotoxischen glykolipiden
DE60031100T2 (de) Hapten modifizierte tumorzellen und verfahren zur herstellung und deren verwendung
DE2735411A1 (de) Verfahren zur herstellung von acellulaeren vaccinen und nach diesem verfahren gewonnene vaccine
DE2547105A1 (de) N-acetyl-muramyl-l-alanyl-d-isoglutamin enthaltende oelfreie adjuvanzien
Gray et al. Brief Communication: Immunotherapy of Cancer: Tumor Suppression and Regression by Cell Walls of Mycobacterium phlei Attached to Oil Droplets
US4504473A (en) Pyridine soluble extract of a microorganism
DE2325299A1 (de) Aus mikroorganismen von der art der mycobakterien erhaltene, nicht-spezifische reizmittel, die eine antitumorimmunitaet hervorrufen und verfahren zu deren herstellung
CH641354A5 (de) Material mit antitumorwirkung und verfahren zu dessen herstellung.
DE2834893C2 (enExample)
EP0445710B1 (de) Verwendung von Zink-Calciumhydroxid, Lecithin und PAO zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen
DE60213785T2 (de) Saponin inaktivierte mykoplasma impfstoffe
DE2829975A1 (de) Antitumor wirksame substanz, deren herstellung und verwendung
DE3323092C2 (de) Pharmazeutisches Präparat
DE3323093C2 (de) Pharmazeutisches Präparat zur Bekämpfung von Tumoren
CA1202903A (en) Stable composition and preparation thereof
DE3323094C2 (enExample)

Legal Events

Date Code Title Description
PFA Name/firm changed

Owner name: RIBI IMMUNOCHEM RESEARCH, INC.

Free format text: RIBI IMMUNOCHEM RESEARCH, INC.#N.E. 581 OLD CORVALLIS ROAD P.O. BOX 1409#HAMILTON/MT (US) -TRANSFERTO- RIBI IMMUNOCHEM RESEARCH, INC.#N.E. 581 OLD CORVALLIS ROAD P.O. BOX 1409#HAMILTON/MT (US)

PL Patent ceased